EVALUATION OF ANTITUMOR ACTIVITY OF SIDDHA DRUG GOWRI CHINTHAMANI CHENDHOORAM (GCC) AGAINST DU 145 CELL LINES
*Dr. S. Ramalingam, Dr. P. Parthibhan, Dr. K. Kanagavalli, Dr. D. Mantela, Dr. P. Porchelvan
Benign prostatic hyperplasia (BPH) is more common in men above 60yrs of age. The second most common disease in men need to go for surgery. The National Institutes of Health, reports more than 7.8 million people got diagnoses with BPH. In Siddha system, Gowri Chinthamani Chendhooram(GCC), a metalo-mineral preparation contains purified sulphur, purified mercury and purified borax helps to treat BPH. The symptoms of BPH are closely related with symptoms of Vatha moothira kirichuram mentioned in Siddha literatures. In pre-clinical studies, the drug shows no toxicity up to level of 200mg/kg bw and the pharmacological activity of GCC revealed by its anti-tumor activity against DU 145 cell line studies. IC50 value of GCC was 15.6 μg/ml, which shows the drug works more on the tumor cell lines. From this preclinical studies, the Siddha drug, GCC should be a new line of treatment for BPH.
Keywords: BPH, antitumor, GCC, DU 145 cell lines, Vatha moothira kirichuram.
[Full Text Article]